Related Experiment Video

Updated: Oct 13, 2025

Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer
12:23

Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer

Published on: August 2, 2018

12.3K

Protein Kinase D: A Potential Therapeutic Target in Prostate Cancer

Adhiraj Roy1, Q Jane Wang1

  • 1Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Molecular and Cellular Pharmacology
|November 12, 2021
PubMed

Insights

Protein kinase D (PKD) regulates cell functions and is implicated in cancer. Specific PKD isoforms show tumor-promoting roles in prostate cancer, offering potential therapeutic targets.

Area of Science:

  • Molecular Biology
  • Cell Signaling
  • Oncology

Background:

  • Protein kinase D (PKD) is a serine/threonine kinase involved in diverse cellular processes.
  • PKD signaling pathways regulate cell proliferation, survival, migration, and angiogenesis.
  • The precise role of PKD in cancer progression is still under investigation.

Purpose of the Study:

  • To elucidate the role of specific Protein kinase D (PKD) isoforms in cancer.
  • To evaluate the potential of PKD isoforms as therapeutic targets in prostate cancer.

Main Methods:

  • Literature review of current research on PKD signaling.
  • Analysis of studies investigating PKD isoform function in prostate cancer models.
  • Assessment of therapeutic strategies targeting PKD.

Main Results:

  • PKD isoforms play varied roles in cellular signaling pathways.
  • Evidence suggests a tumor-promoting function for certain PKD isoforms in prostate cancer.
  • Selective targeting of these isoforms may offer a novel therapeutic approach.

Conclusions:

  • Protein kinase D (PKD) signaling is crucial for cellular regulation and cancer development.
  • Specific PKD isoforms are implicated in promoting prostate cancer growth.
  • Targeting these PKD isoforms presents a promising avenue for cancer therapy.
Keywords:
Prostate cancerProtein kinase DSignal transductionTherapeutic target

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.3K
Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

7.6K

Related Concept Videos

Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
13.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.2K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K